Shanghai Junshi Biosciences Co., Ltd.
688180
Xếp hạng trong cổ phiếu
#3910
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise... Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
Giá cổ phiếu
$4.54
Vốn hóa thị trường
$4.16B
Thay đổi (1 ngày)
-2.35%
Thay đổi (1 năm)
-16.02%
Quốc gia
CN
Giao dịch Shanghai Junshi Biosciences Co., Ltd. (688180)
Danh mục
Healthcare
Tỷ lệ P/S của Shanghai Junshi Biosciences Co., Ltd. (688180)
Tỷ lệ P/S vào October 2026 TTM: 9.19
Theo các báo cáo tài chính và giá cổ phiếu mới nhất của Shanghai Junshi Biosciences Co., Ltd., tỷ lệ P/S hiện tại (TTM) là 9.19. Vào cuối năm 2024, công ty có P/S là 13.82.
Lịch sử tỷ lệ P/S của Shanghai Junshi Biosciences Co., Ltd. từ 2014 đến 2026
Tỷ lệ P/S vào cuối mỗi năm
| Năm | Tỷ lệ P/S | Thay đổi |
|---|---|---|
| 2026 (TTM) | 9.19 | -33.12% |
| 2025 | 13.74 | -0.58% |
| 2024 | 13.82 | -49.56% |
| 2023 | 27.40 | -30.66% |
| 2022 | 39.51 | 166.78% |
| 2021 | 14.81 | -64.56% |
| 2020 | 41.80 | -72.44% |
| 2019 | 151.68 | -99.84% |
| 2018 | 97.30K | 27.56% |
| 2017 | 76.28K | 271.51% |
| 2016 | 20.53K | 76.04% |
| 2015 | 11.66K | 108.49% |
| 2014 | 5.59K | 0.00% |
Tỷ lệ P/S của các công ty tương tự hoặc đối thủ cạnh tranh
| Công ty | Tỷ lệ P/S | Chênh lệch Tỷ lệ P/S | Quốc gia |
|---|---|---|---|
| 10.02 | 9.06% |
US
|
|
| 40.55 | 341.28% |
US
|
|
| 4.19 | -54.39% |
AU
|
|
| 10.44 | 13.64% |
NL
|
|
| 4.52 | -50.83% |
BE
|
